Pasireotide LAR for Acromegaly but Hyperglycemia a DrawbackPasireotide LAR for Acromegaly but Hyperglycemia a Drawback
Pasireotide LAR improves response in acromegaly patients poorly controlled on first-generation somatostatins, but hyperglycemia remains an issue as the agent awaits regulatory approval for this indication. Medscape Medical News
In this study, we aimed to evaluate the presence of glucose metabolism abnormalities and their impact on IGF-1 levels in patients with acromegaly. Ninety-three patients with acromegaly (n=93; 52 males/41 females) were included in this study. Patients were separated into three groups such as; normal glucose tolerance (n=23, 25%), prediabetes (n=38, 41%), and diabetes mellitus (n=32, 34%). Insulin resistance was calculated with homeostasis model assessment (HOMA). HOMA-IR> 2.5 or ≤2.5 were defined as insulin resistant or noninsulin resistant groups, respectively. Groups were compared in terms of factors that may...
Funding Opportunity PA-18-741 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and ...
Conclusion: Our findings underscore the importance of an integral approach when managing these patients, focusing not only on the control of GH and IGF-1 levels but also on the timely diagnosis and the specific treatment of each co-morbidity. PMID: 29618021 [PubMed - as supplied by publisher]
Patients with acromegaly may be at continued risk for glucose disorders -- even after hypersecretion of growth hormone has been controlled.Journal of the Endocrine Society
ConclusionThe most important factors affecting gonadal functions, excluding central hypogonadism, are hyperprolactinemia and the duration of the indolent period before diagnosis of acromegaly. AMH levels in the majority of patients were found to be lower than the expected age. Despite the decreased ovarian reserve, fertilization and normal birth can be achieved with careful surveillance.
Conclusion There is some reduction in cardiovascular risk factors with control of the disease, but possibly without the return to basal levels. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Abstract | Full text
AbstractPurpose1) To compare the retinal, choroidal, Haller ’s layer, and Sattler’s/choriocapillaris thicknesses of untreated acromegaly patients without chiasm compression or diabetes mellitus and healthy controls. 2) To evaluate the correlations of retinal and choroidal thicknesses with serum growth hormone (GH) and insulin-like growth factor 1 (IGF) b urden.MethodsThis prospective, case-control study included 27 untreated acromegaly patients and 27 sex-matched and age-matched controls. Subfoveal choroidal, Haller ’s layer and Sattler’s/choriocapillaris thicknesses were determined by enhanced-dept...
According to a French study, published in theJournal of the Endocrine Society,even acromegaly patients in remission have an increased risk of developing diabetes and related metabolic disorders.Healio
Conclusion The high proliferative, but absence of non-proliferative retinopathy in our patients with acromegaly may reflect the pathogenic effect of IGF-1 on neovascularization. IGF-1 may play an important role in proliferative retinopathy, but may play no role in non-proliferative retinopathy.
Introduction: Cardiovascular diseases are main risk factor of death and disability in patient with type 2 diabetes mellitus (T2DM), acromegaly, hypercortisolism, thyrotoxicosis . Sleep apnea (SA) plays an important role in development of cardiovascular complications in patients with different endocrine disorders. Screening for sleep apnea is not included in the standards of examination of patients with endocrinopathies. The aim of study was to estimate need of sleep apnea screening in patients with endocrine disorders.